Integra Lifesciences Holdings (IART) Cash from Operations (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Cash from Operations data on file, last reported at 9803000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 187.08% year-over-year to 9803000.0; the trailing twelve-month figure through Mar 2026 stood at 71444000.0 (down 30.21% YoY), and the FY2025 full-year result was 50384000.0, down 61.06% from the prior year.
• Cash from Operations fell to 9803000.0 in Q1 2026, from 11816000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 85334000.0 in Q4 2022 to a low of 11257000.0 in Q1 2025.
• A 5-year average of 34940764.71 and a median of 28279000.0 in 2023 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations slumped 171.45% in 2025 and jumped 187.08% in 2026, its largest moves.
• Tracing IART's Cash from Operations over 5 years: stood at 85334000.0 in 2022, then plunged by 31.15% to 58750000.0 in 2023, then slipped by 13.63% to 50740000.0 in 2024, then slumped by 76.71% to 11816000.0 in 2025, then dropped by 17.04% to 9803000.0 in 2026.
• Business Quant data shows IART's Cash from Operations at 9803000.0 in Q1 2026, 11816000.0 in Q4 2025, and 40906000.0 in Q3 2025.